# PRESS RELEASE BODY Tampa Bay Biotech today announced the launch of OncoDetect AI, an advanced diagnostic platform designed to improve early cancer detection across Florida's community hospital network. The proprietary technology utilizes machine learning algorithms to identify breast, colorectal and lung cancers in their earliest stages, enabling physicians to initiate treatment when patient outcomes are most favorable. OncoDetect AI integrates seamlessly with existing hospital imaging systems and electronic health records, requiring minimal infrastructure modifications. The platform analyzes medical imaging data in real time, providing clinicians with risk stratification reports within minutes. Initial clinical trials demonstrated a 23% improvement in early-stage cancer identification compared to traditional diagnostic methods. "OncoDetect AI represents a significant advancement in our mission to democratize cancer detection across Florida's healthcare landscape," said Dr. Margaret Chen, Chief Medical Officer at Tampa Bay Biotech. "This platform empowers community hospitals with technology previously available only at major academic medical centers, ultimately saving lives through earlier intervention." The company has partnered with 12 community hospitals across the Tampa Bay region for the platform's initial rollout, with expansion planned to additional Florida facilities by Q3 2024. Tampa Bay Biotech will offer training and ongoing technical support to ensure seamless implementation. **About Tampa Bay Biotech** Tampa Bay Biotech is a healthcare technology innovator specializing in AI-driven diagnostic solutions. Founded in 2019, the company develops software platforms that enhance clinical decision-making and improve patient outcomes across multiple disease states. Headquartered in Tampa, Florida, Tampa Bay Biotech collaborates with healthcare systems, academic institutions and research organizations nationwide.